Shortly after Eli Lilly’s Alzheimer’s drug failed in a massive clinical trial last November, a small company called Accera touted an alternative: a drug to improve how the brain processes sugar. Accera hoped to upset the long-held theory that Alzheimer’s is caused by a buildup of a toxic protein called amyloid. According to that hypothesis, the...